CION Ameerpet
Immunotherapy · Autoimmune Disease, Transplant & Contraindications
Immunotherapy With Rheumatoid Arthritis — Flares, Medicines and Monitoring
Rheumatoid arthritis is the commonest autoimmune condition to sit alongside a cancer diagnosis, and the one most often answered with a general rule instead of an assessment. The honest answer is usually yes, with closer monitoring, not no. This page covers the three things patients actually ask: will it flare, can your arthritis medicines continue, and what monitoring you will be on.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- A caution, not an exclusion — ASCO, ESMO and NCCN guidance supports assessing patients with rheumatoid arthritis case by case — not ruling them out as a group.
- The flare risk is real but usually manageable — Reported series describe flares in a substantial minority, most handled by holding treatment and treating the flare, with resumption considered case by case.
- Arthritis medicines are reviewed, not automatically stopped — Painkillers and low-dose steroids commonly continue; biologic and targeted synthetic drugs get the closest look — and nothing changes without your rheumatologist.
- Lung involvement changes the weighting — Interstitial lung disease from rheumatoid arthritis is the highest-caution situation here, and needs baseline chest imaging before any decision.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The short answer
Can You Have Immunotherapy If You Have Rheumatoid Arthritis?
Usually yes, with closer monitoring. Rheumatoid arthritis is a caution, not an automatic exclusion. Guidance from ASCO, ESMO and NCCN supports assessing these patients case by case. What decides it is how active your arthritis is, what medicines control it, whether your lungs are involved, and who is watching you.
Rheumatoid arthritis is the autoimmune condition most often sitting alongside a cancer diagnosis, so this overlap comes up more than any other. It is also the one most often answered badly — with a general rule about “autoimmune patients” rather than a look at your disease activity, your drug list and your chest. A no reached that way has not answered your question.
There are situations where the caution is real and the answer may genuinely be no, or not yet. This page sets out the three things patients actually ask: whether it will flare, whether your arthritis medicines can continue, and what the monitoring looks like. The broader picture across all autoimmune conditions is in Can You Have Immunotherapy With an Autoimmune Disease?
This page is general patient education. It cannot tell you whether immunotherapy is safe for you. That assessment needs your disease activity, your current medicines, your recent bloods and your scans in front of a medical oncologist working with your rheumatologist.
Question 1 of 3
Will Immunotherapy Make Your Rheumatoid Arthritis Flare?
It can. Published series report flares in a substantial minority of patients on checkpoint inhibitors. The figures vary too widely between series to quote one reliable number. Most reported flares looked like the arthritis the patient already knew, and most were managed by holding treatment and treating the flare.
Two different things can happen, and they get muddled constantly. The first is a flare of the rheumatoid arthritis you already have. The second is a new immune-related side effect in an organ your arthritis has never touched — thyroid, bowel, liver, lung or skin. Having rheumatoid arthritis raises the first risk. It does not protect you from the second.
Timing follows a rough pattern. Flares of existing arthritis are most often reported in the first weeks to few months after starting. New immune-related side effects can appear at any point, including weeks or months after treatment finishes. That is why the monitoring schedule for you is tighter at the front and does not simply stop at the last cycle.
The honest limitation is the evidence itself. Patients with active autoimmune disease were largely excluded from the registration trials, so what exists is retrospective series and registry data rather than randomised evidence. Anyone quoting you a confident single percentage for rheumatoid arthritis specifically is ahead of the data.
What changes the outcome in practice is not the flare. It is how fast it is recognised. Joint stiffness you would normally sit out for a fortnight is worth reporting the same week once you are on immunotherapy, because your team needs to know whether it is your arthritis or something new.
Did you know?
Immunotherapy is given as day care at CION centres, and the appointment where eligibility is decided is a consultation, not an infusion. Nothing is started on the day you first discuss it. Bring your rheumatologist’s latest letter and a full list of your current medicines with doses — that single list moves the conversation further than any test result.
Risk is stratified, not binary
Which Rheumatoid Arthritis Situations Need the Most Caution?
Arthritis in remission off all medicines sits at one end. An active flare, lung involvement, or vasculitis sits at the other. Where you fall changes the monitoring plan and who has to be in the discussion — it rarely produces a flat no on its own.
| Your situation | How it is usually weighed | Who needs to be in the discussion |
|---|---|---|
| Rheumatoid arthritis in remission, off all immunosuppression | Generally proceeds, with standard immunotherapy monitoring plus a documented flare plan agreed before the first dose. | Medical oncologist, with your rheumatologist informed |
| Well-controlled arthritis on a conventional disease-modifying drug alone | Usually proceeds. The drug is often continued to keep the arthritis stable, reviewed rather than stopped by default. | Medical oncologist and prescribing rheumatologist |
| Controlled arthritis on a biologic or targeted synthetic disease-modifying drug | Proceeds after review. This group needs the most thought, because those drugs suppress the same immune activity immunotherapy is trying to release, and published experience of continuing them is limited. | Medical oncologist and rheumatologist, jointly |
| Arthritis needing a maintenance steroid dose above the low-dose threshold | Reviewed before starting. Guidance commonly flags a prednisolone-equivalent above roughly 10 mg a day as a dose to reduce or reassess first, where the arthritis safely allows it. | Medical oncologist and prescribing rheumatologist |
| Active flare now, or a severe flare in recent months | Usually deferred rather than refused. The flare is settled first and the decision revisited — starting mid-flare makes both problems harder to read. | Medical oncologist and rheumatologist, jointly |
| Rheumatoid arthritis with interstitial lung disease | The highest-caution situation in this group. Damaged lung leaves less reserve if immune-related pneumonitis develops, so baseline chest imaging and lung function are assessed before any decision. | Medical oncologist and respiratory physician, with rheumatology |
| Arthritis with vasculitis or other significant organ involvement | Weighed against how much reserve the affected organ has left. Monitoring is intensified and the threshold for holding treatment is set before starting, not improvised later. | Medical oncologist and the relevant organ specialist |
General patterns at guidance level only. Your own team’s assessment of your case overrides anything in this table, in either direction. If bowel disease rather than arthritis is your situation, Immunotherapy With Inflammatory Bowel Disease covers that overlap instead.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
An Assessed No Is Fine. An Assumed No Is Not.
If nobody has looked at your disease activity, your drug list and your chest, nobody has actually answered your question yet. Ask for that review.
Question 2 of 3
Can Your Arthritis Medicines Continue During Immunotherapy?
Often yes. Every group is reviewed before you start, but review is not the same as stop. The aim is to keep your arthritis stable without blunting what immunotherapy is trying to do, and that balance is set for you rather than by a blanket rule.
| Medicine group | Usual approach before and during immunotherapy | Who decides |
|---|---|---|
| Simple painkillers and anti-inflammatories | Usually continue. Tell your oncology team what you take and how often, because regular use can mask an early symptom the team wants to see. | Medical oncologist |
| Corticosteroids | Low maintenance doses are commonly continued. Higher doses are reviewed and reduced where the arthritis safely allows, because higher-dose steroids at baseline may blunt the treatment response. Tapered, never stopped abruptly. | Prescribing rheumatologist with the medical oncologist |
| Conventional disease-modifying drugs | Frequently continued to hold the arthritis stable. The decision is individualised rather than automatic in either direction. | Prescribing rheumatologist with the medical oncologist |
| Biologic disease-modifying drugs | The group most likely to be reviewed and sometimes held, because they suppress the same immune activity immunotherapy releases. Some are also used later to treat a severe flare or an immune-related side effect. | Rheumatologist and medical oncologist, jointly |
| Targeted synthetic disease-modifying drugs | Reviewed case by case. Published experience alongside checkpoint inhibitors is limited, so the plan is made specifically for you and written down. | Rheumatologist and medical oncologist, jointly |
| Ayurvedic, homeopathic and herbal preparations, and supplements | Bring the actual packets to the consultation. Nobody is asking you to give up a system you trust — the team needs to know what is in them, because some preparations affect liver blood tests or interact with steroids, and an unexplained result costs you a cycle. | Medical oncologist, once the full list is known |
One rule holds across every row: nothing is started, stopped or reduced by you alone. Stopping arthritis medicines on your own is the fastest way to trigger the flare everyone is trying to avoid.
Question 3 of 3
What Monitoring Will You Actually Be On?
More than the standard schedule, and agreed in writing before the first dose. The point of a baseline is simple: it makes a later change measurable instead of arguable.
1
Before the first dose — the baseline
How active your arthritis is now, which joints are involved, inflammatory markers, blood counts, and thyroid, liver and kidney function. Chest imaging and lung function if there is any suggestion of lung involvement. This is a fresh assessment, not a line copied from an old discharge summary.
2
The first few months — the tightest watch
This is when flares of existing arthritis are most often reported, so reviews sit closer together at the start. Expect to be asked specific questions about morning stiffness and which joints, not just whether you feel well.
3
Every cycle — bloods and a symptom review
Blood counts and thyroid, liver and kidney function before each dose, read against your own baseline rather than a general reference range. Response is assessed on imaging at intervals your team sets; response-assessment PET-CT is coordinated at partner imaging centres rather than done in-house.
4
Between cycles — a written flare plan and a named contact
Which symptoms mean call today, who to call and on which number, what is held while it is sorted out, who prescribes steroids if they are needed, and the agreed threshold for stopping. If nobody has written this down, ask for it before you start. The CION helpline is 1800 202 8726.
5
After treatment ends — the handover back
Immune-related side effects can appear after the last dose, and thyroid problems in particular can surface late. Your rheumatologist should get a written summary of what happened, what was given for it, and what to watch for — so your arthritis care picks up where it left off.
Telling them apart
Is This an Arthritis Flare or a New Immunotherapy Side Effect?
Often you cannot tell, and you are not expected to. Report it and let the team work it out. These five distinctions are what they will ask you about.
- Your usual joints, your usual pattern — symmetrical small-joint pain and morning stiffness you recognise is more likely a flare of your arthritis.
- Joints your arthritis has never touched — new swelling in a large joint, or a pattern you do not recognise, may be a new immune-related inflammatory arthritis instead.
- Anything outside the joints — that is not your rheumatoid arthritis talking. Bowel, liver, thyroid, skin and lung symptoms are assessed as immune-related until proven otherwise.
- How fast it came on — a flare usually builds over days in a familiar way. Something that arrives quickly, or keeps worsening, gets escalated rather than watched.
- Whether it responds as usual — a flare that ignores what normally settles it is a reason to call, not a reason to double the dose yourself.
Some symptoms should not wait for a scheduled review at all. New breathlessness or a persistent cough, chest pain, severe or bloody diarrhoea, yellowing of the eyes or skin, new muscle weakness, drooping eyelids or double vision: contact your oncology team the same day, and go to the emergency department now if it is severe or getting worse. Do not manage these at home and do not wait for the next cycle. If you cannot reach your treating doctor, call 1800 202 8726.
You are not an exception
Get the Eligibility Question Answered Properly
A medical oncologist, working with the rheumatologist who manages your arthritis, can tell you where you actually stand — and what the monitoring plan would look like.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Immunotherapy and Rheumatoid Arthritis — Your Questions Answered
Will immunotherapy make your rheumatoid arthritis flare?
It can, and rheumatoid arthritis is the autoimmune condition most often involved. Published series report flares in a substantial minority of patients, and the figures vary too widely between series for any single number to be reliable. Most reported flares looked like the arthritis the patient already knew, with morning stiffness and symmetrical small-joint pain, rather than something new. Most were managed by holding immunotherapy and treating the flare with steroids or the arthritis therapy itself, and a proportion of patients resumed immunotherapy afterwards. Whether you resume is decided case by case by your medical oncologist with your rheumatologist, not by a general rule.
Can you continue your rheumatoid arthritis medicines during immunotherapy?
Often yes, but every group is reviewed before you start and nothing is changed by you alone. Simple painkillers usually continue. Low-dose steroids are commonly continued. Conventional disease-modifying drugs are frequently kept going to hold the arthritis stable. Biologic and targeted synthetic disease-modifying drugs are the group most likely to be reviewed, because they suppress the same immune activity immunotherapy is trying to release, and the published experience of continuing them alongside treatment is limited. The decision belongs to the rheumatologist who prescribed them, working with your medical oncologist. Stopping them yourself is the fastest way to trigger the flare everyone is trying to avoid.
Do you have to stop steroids before immunotherapy?
Not always, and not abruptly. What is reviewed is the dose, not the fact that you take them. Guidance commonly flags a prednisolone-equivalent above roughly 10 mg a day as a baseline dose to try to reduce or reassess before starting, because higher-dose steroids may blunt what immunotherapy is trying to do. Where your arthritis will not safely allow that reduction, that is a legitimate clinical finding and part of the discussion, not a failure. Any change is made by the doctor who prescribed the steroids, tapered rather than stopped, and never arranged over the phone by someone who has not seen you.
What monitoring do you need on immunotherapy if you have rheumatoid arthritis?
More than the standard schedule, agreed in writing before the first dose. Expect a baseline record of how active your arthritis is now, inflammatory markers, blood counts, and thyroid, liver and kidney function, so any later change can be measured against a known starting point. Baseline chest imaging matters if there is any lung involvement from the arthritis. Bloods and a symptom review are repeated at each cycle, with the tightest watch over the first few months, when flares are most often reported. You should leave with a named contact and a written list of the symptoms that mean call the same day.
How do you tell a rheumatoid arthritis flare from a new immunotherapy side effect?
Often you cannot, and that is exactly why you report it rather than deciding yourself. Pain and stiffness in the same joints your arthritis has always affected, in your usual pattern, is more likely a flare. Swelling in joints your arthritis has never touched, or a pattern you do not recognise, may be a new immune-related inflammatory arthritis. Symptoms outside the joints are the ones not to sit on at all: new breathlessness or a persistent cough, severe or bloody diarrhoea, yellowing of the eyes or skin, new muscle weakness, or chest pain. Contact your oncology team the same day, and go to the emergency department now if it is severe or getting worse.
Is rheumatoid arthritis a reason to be refused immunotherapy?
Rheumatoid arthritis on its own is a caution, not an automatic exclusion. Current guidance from ASCO, ESMO and NCCN supports assessing these patients case by case rather than ruling them out as a group. Some situations do carry far more weight, particularly an active flare, lung involvement from the arthritis, or significant organ damage, and those are weighed jointly rather than by the oncology team alone. A properly reasoned no names your specific situation and sets out the alternative plan. If you were told no without an assessment, and without your rheumatologist being asked, a second opinion from a medical oncologist is reasonable.
This page is general patient-education information, not a substitute for the assessment your own medical oncologist and rheumatologist make for your specific case.